Predicting autosomal dominant polycystic kidney disease progression: review of promising Serum and urine biomarkers

Scientific paper - Review paper

• Author: Iva Sorić Hosman
• Author: Andrea Cvitković Roić
• Author: Margareta Fištrek Prlić
• Author: Ivana Vuković Brinar
• Author: Lovro Lamot
• Author's institution: University of Zagreb; School of Medicine; (Department of Pediatrics)
• Scientific / art field, discipline and subdiscipline: BIOMEDICINE AND HEALTHCARE; Clinical Medical Sciences; Pediatrics

Abstract (english)

Autosomal dominant polycystic kidney disease (ADPKD) is one of the leading causes of end-stage renal disease. In spite of the recent tremendous progress in the understanding of ADPKD pathogenesis, the molecular mechanisms of the disease remain incompletely understood. Considering emerging new targeted therapies for ADPKD, it has become crucial to disclose easily measurable and widely available biomarkers for identifying patients with future rapid disease progression. This review encompasses all the research with a shared goal of identifying promising serum or urine biomarkers for predicting ADPKD progression or response to therapy. The rate of the ADPKD progress varies significantly between patients. The phenotypic variability is only partly explained by the underlying genetic lesion diversity. Considering significant decline in kidney function in ADPKD is not usually evident until at least 50% of the parenchyma has been destroyed, conventional kidney function measures, such as glomerular filtration rate (GFR), are not suitable for monitoring disease progression in ADPKD, particularly in its early stages. Since polycystic kidney enlargement usually precedes the decline in GFR, height-adjusted total kidney volume (ht-TKV) has been accepted as an early biomarker for assessing disease severity in ADPKD patients. However, since measuring ht-TKV is time-consuming and observer-dependent, the identification of a sensitive and quickly measurable biomarker is of a great interest for everyday clinical practice. Throughout the last decade, due to development of proteomic and metabolomic techniques and the enlightenment of multiple molecular pathways involved in the ADPKD pathogenesis, a number of urine and serum protein biomarkers have been investigated in ADPKD patients, some of which seem worth of further exploring. These include copeptin, angiotensinogen, monocyte chemoattractant protein 1, kidney injury molecule-1 and urine-to-plasma urea ratio among many others. The aim of the current review is to provide an overview of all of the published evidence on potentially clinically valuable serum and urine biomarkers that could be used for predicting disease progression or response to therapy in patients with ADPKD. Hopefully, this review will encourage future longitudinal prospective clinical studies evaluating proposed biomarkers as prognostic tools to improve management and outcome of ADPKD patients in everyday clinical practice.

• Keywords (english): angiotensinogen (AGT); autosomal dominant polycystic kidney disease (ADPKD); copeptin; predictive biomarker; prognostic biomarker; urinary biomarkers; urinary metabolomics; urinary proteomics
• Language: english
• Publication type: Scientific paper - Review paper
• Publication status: Published
• Peer review: Peer review
• Publication version: Accepted version
• Journal title: Frontiers in Pediatrics
• Numbering: vol. 11, 1274435
• e-ISSN: 2296-2360
• DOI: https://doi.org/10.3389/fped.2023.1274435
• URN:NBN: urn:nbn:hr:105:644350
• Publication: 2023-11-10
• Document URL: https://www.frontiersin.org/articles/10.3389/fped.2023.1274435/full
• Type of resource: Text
• Access conditions: Open access
• Created on: 2024-03-12 09:00:55